Keyphrases
Deep Brain Stimulation
100%
Patients with Parkinson's Disease
100%
Microelectrode Recording
100%
Procedural Sedation
100%
Clinical Outcomes
100%
Analgesia
87%
Local Anesthesia
87%
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
50%
Parkinson Patients
37%
Unified Parkinson's Disease Rating Scale (UPDRS)
37%
Deep Brain Stimulation Surgery
25%
Daily Dose
25%
Levodopa
25%
Before Surgery
12%
Preoperative Evaluation
12%
Parkinson's Disease
12%
Activities of Daily Living
12%
Non-associated
12%
Between-group
12%
Stroop Color-word Test
12%
Executive Function
12%
Non-motor
12%
Rating Score
12%
Motor Function
12%
Patient Comfort
12%
Trail Making Test
12%
Verbal Fluency
12%
Clonidine
12%
Advanced Parkinson's Disease
12%
Cognitive Alterations
12%
Movement Disorder Society
12%
Motor Outcome
12%
Routine Treatment
12%
Disease Score
12%
Perioperative Adverse Events
12%
Remifentanil
12%
Dexmedetomidine
12%
Dosage Reduction
12%
Implantation Surgery
12%
Postoperative Adverse Events
12%
Surgical Adverse Events
12%
Medicine and Dentistry
Analgesia
100%
Parkinson's Disease
100%
Local Anesthesia
100%
Electrical Brain Stimulation
100%
Microelectrode
100%
Subthalamic Nucleus
57%
Unified Parkinson's Disease Rating Scale
42%
Adverse Event
28%
Drug Therapy
28%
Levodopa
28%
Stereotypic Movement Disorder
14%
Observational Study
14%
Motor Performance
14%
Activities of Daily Living
14%
Executive Function
14%
Drug Dose Reduction
14%
Clonidine
14%
Remifentanil
14%
Myelodysplastic Syndrome
14%
Stroop Test
14%
Patient Comfort
14%
Dexmedetomidine
14%
Trail Making Test
14%
INIS
patients
100%
anesthesia
100%
stimulation
100%
brain
100%
nervous system diseases
100%
surgery
71%
nuclei
57%
motors
42%
comparative evaluations
28%
reduction
14%
assessments
14%
color
14%
Neuroscience
Electrical Brain Stimulation
100%
Parkinson's Disease
100%
Subthalamic Nucleus
66%
L-DOPA
33%
Stereotypic Movement Disorder
16%
Remifentanil
16%
Dexmedetomidine
16%
Executive Function
16%
Clonidine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Adverse Event
33%
Levodopa
33%
Motor Dysfunction
16%
Observational Study
16%
Clonidine
16%
Myelodysplastic Syndrome
16%
Dexmedetomidine
16%
Remifentanil
16%